Literature DB >> 31018108

The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.

Charis L Himeda1, Peter L Jones1.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD), a progressive myopathy that afflicts individuals of all ages, provides a powerful model of the complex interplay between genetic and epigenetic mechanisms of chromatin regulation. FSHD is caused by dysregulation of a macrosatellite repeat, either by contraction of the repeat or by mutations in silencing proteins. Both cases lead to chromatin relaxation and, in the context of a permissive allele, aberrant expression of the DUX4 gene in skeletal muscle. DUX4 is a pioneer transcription factor that activates a program of gene expression during early human development, after which its expression is silenced in most somatic cells. When misexpressed in FSHD skeletal muscle, the DUX4 program leads to accumulated muscle pathology. Epigenetic regulators of the disease locus represent particularly attractive therapeutic targets for FSHD, as many are not global modifiers of the genome, and altering their expression or activity should allow correction of the underlying defect.

Entities:  

Keywords:  DUX4; FSHD; chromatin; epigenetics; facioscapulohumeral muscular dystrophy; muscular dystrophy; skeletal muscle

Mesh:

Substances:

Year:  2019        PMID: 31018108     DOI: 10.1146/annurev-genom-083118-014933

Source DB:  PubMed          Journal:  Annu Rev Genomics Hum Genet        ISSN: 1527-8204            Impact factor:   8.929


  22 in total

1.  Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Aiping Zhang; Hunain Khawaja; Sreetama Sen Chandra; Takako Jones; Peter Jones; Yi-Wen Chen; Toshifumi Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

2.  Post-translational Modification in Muscular Dystrophies.

Authors:  Martina Sandonà; Valentina Saccone
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 3.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

4.  Proximity ligation assay to detect DUX4 protein in FSHD1 muscle: a pilot study.

Authors:  Mary Lou Beermann; Sachiko Homma; Jeffrey Boone Miller
Journal:  BMC Res Notes       Date:  2022-05-10

Review 5.  Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy.

Authors:  Justin Cohen; Alec DeSimone; Monkol Lek; Angela Lek
Journal:  Trends Mol Med       Date:  2020-10-19       Impact factor: 11.951

6.  Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy.

Authors:  Angela Lek; Yuanfan Zhang; Keryn G Woodman; Shushu Huang; Alec M DeSimone; Justin Cohen; Vincent Ho; James Conner; Lillian Mead; Andrew Kodani; Anna Pakula; Neville Sanjana; Oliver D King; Peter L Jones; Kathryn R Wagner; Monkol Lek; Louis M Kunkel
Journal:  Sci Transl Med       Date:  2020-03-25       Impact factor: 17.956

7.  ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.

Authors:  Joanna DeSalvo; Yuguang Ban; Luyuan Li; Xiaodian Sun; Zhijie Jiang; Darcy A Kerr; Mahsa Khanlari; Maria Boulina; Mario R Capecchi; Juha M Partanen; Lin Chen; Tadashi Kondo; David M Ornitz; Jonathan C Trent; Josiane E Eid
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

8.  DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.

Authors:  Kenji Rowel Q Lim; Adam Bittel; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Yiqing Huang; Kasia Dzierlega; Aiping Zhang; Yi-Wen Chen; Toshifumi Yokota
Journal:  Mol Ther       Date:  2020-10-15       Impact factor: 11.454

9.  p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models.

Authors:  Bradley D Weaver; Christina M Smith; Edward J Grow; Jingtao Guo; Paula Stein; Sean C Shadle; Peter G Hendrickson; Nicholas E Johnson; Russell J Butterfield; Roberta Menafra; Susan L Kloet; Silvère M van der Maarel; Carmen J Williams; Bradley R Cairns
Journal:  Nat Genet       Date:  2021-07-15       Impact factor: 38.330

10.  Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy.

Authors:  Kohei Hamanaka; Darina Šikrová; Satomi Mitsuhashi; Hiroki Masuda; Yukari Sekiguchi; Atsuhiko Sugiyama; Kazumoto Shibuya; Richard J L F Lemmers; Remko Goossens; Megumu Ogawa; Koji Nagao; Chikashi Obuse; Satoru Noguchi; Yukiko K Hayashi; Satoshi Kuwabara; Judit Balog; Ichizo Nishino; Silvère M van der Maarel
Journal:  Neurology       Date:  2020-05-28       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.